March 2024 Br J Cardiol 2024;31:31 doi:10.5837/bjc.2024.012
Ishtiaq Rahman, Cristina Ruiz Segria, Jason Trevis, Sharareh Vahabi, Richard Graham, Jeet Thambyrajah, Ralph White, Andrew Goodwin, Simon Kendall, Enoch Akowuah
Introduction Timely corrective surgery for severe mitral regurgitation (MR) reduces the risk of limiting symptoms and irreversible left ventricular dysfunction.1,2 Left untreated, severe MR carries a poor prognosis. In asymptomatic patients, the estimated five-year rates of death from any cause, death from cardiac causes and adverse cardiac events (death, heart failure or new atrial fibrillation), are 22%, 14% and 33%, respectively.2 The prognosis for symptomatic patients is significantly worse, and further adversely affected by older age and comorbidities, including atrial fibrillation, pulmonary hypertension, left atrial dilatation, and re
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits